2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity

Sherry Y. Wu, Xianbin Yang, Kshipra M. Gharpure, Hiroto Hatakeyama, Martin Egli, Michael H. McGuire, Archana S. Nagaraja, Takahito M. Miyake, Rajesha Rupaimoole, Chad V. Pecot, Morgan Taylor, Sunila Pradeep, Malgorzata Sierant, Cristian Rodriguez-Aguayo, Hyun J. Choi, Rebecca A. Previs, Guillermo N. Armaiz-Pena, Li Huang, Carlos Martinez, Tom Hassell & 18 others Cristina Ivan, Vasudha Sehgal, Richa Singhania, Hee Dong Han, Chang Su, Ji Hoon Kim, Heather J. Dalton, Chandra Kovvali, Khandan Keyomarsi, Nigel A.J. McMillan, Willem W. Overwijk, Jinsong Liu, Ju Seog Lee, Keith A. Baggerly, Gabriel Lopez-Berestein, Prahlad T. Ram, Barbara Nawrot, Anil K. Sood

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Improving small interfering RNA (siRNA) efficacy in target cell populations remains a challenge to its clinical implementation. Here, we report a chemical modification, consisting of phosphorodithioate (PS2) and 2′-O-Methyl (2′-OMe) MePS2 on one nucleotide that significantly enhances potency and resistance to degradation for various siRNAs. We find enhanced potency stems from an unforeseen increase in siRNA loading to the RNA-induced silencing complex, likely due to the unique interaction mediated by 2′-OMe and PS2. We demonstrate the therapeutic utility of MePS2 siRNAs in chemoresistant ovarian cancer mouse models via targeting GRAM domain containing 1B (GRAMD1B), a protein involved in chemoresistance. GRAMD1B silencing is achieved in tumours following MePS2-modified siRNA treatment, leading to a synergistic anti-tumour effect in combination with paclitaxel. Given the previously limited success in enhancing siRNA potency with chemically modified siRNAs, our findings represent an important advance in siRNA design with the potential for application in numerous cancer types.

Original languageEnglish
Article number3459
JournalNature Communications
Volume5
DOIs
Publication statusPublished - 2014 Mar 12

Fingerprint

Reduced instruction set computing
Small Interfering RNA
Tumors
tumors
cancer
nucleotides
stems
mice
Neoplasms
degradation
proteins
RNA-Induced Silencing Complex
Health Services Needs and Demand
Chemical modification
Paclitaxel
Ovarian Neoplasms
interactions
Nucleotides
Cells
phosphorodithioic acid

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Wu, S. Y., Yang, X., Gharpure, K. M., Hatakeyama, H., Egli, M., McGuire, M. H., ... Sood, A. K. (2014). 2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications, 5, [3459]. https://doi.org/10.1038/ncomms4459

2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. / Wu, Sherry Y.; Yang, Xianbin; Gharpure, Kshipra M.; Hatakeyama, Hiroto; Egli, Martin; McGuire, Michael H.; Nagaraja, Archana S.; Miyake, Takahito M.; Rupaimoole, Rajesha; Pecot, Chad V.; Taylor, Morgan; Pradeep, Sunila; Sierant, Malgorzata; Rodriguez-Aguayo, Cristian; Choi, Hyun J.; Previs, Rebecca A.; Armaiz-Pena, Guillermo N.; Huang, Li; Martinez, Carlos; Hassell, Tom; Ivan, Cristina; Sehgal, Vasudha; Singhania, Richa; Han, Hee Dong; Su, Chang; Kim, Ji Hoon; Dalton, Heather J.; Kovvali, Chandra; Keyomarsi, Khandan; McMillan, Nigel A.J.; Overwijk, Willem W.; Liu, Jinsong; Lee, Ju Seog; Baggerly, Keith A.; Lopez-Berestein, Gabriel; Ram, Prahlad T.; Nawrot, Barbara; Sood, Anil K.

In: Nature Communications, Vol. 5, 3459, 12.03.2014.

Research output: Contribution to journalArticle

Wu, SY, Yang, X, Gharpure, KM, Hatakeyama, H, Egli, M, McGuire, MH, Nagaraja, AS, Miyake, TM, Rupaimoole, R, Pecot, CV, Taylor, M, Pradeep, S, Sierant, M, Rodriguez-Aguayo, C, Choi, HJ, Previs, RA, Armaiz-Pena, GN, Huang, L, Martinez, C, Hassell, T, Ivan, C, Sehgal, V, Singhania, R, Han, HD, Su, C, Kim, JH, Dalton, HJ, Kovvali, C, Keyomarsi, K, McMillan, NAJ, Overwijk, WW, Liu, J, Lee, JS, Baggerly, KA, Lopez-Berestein, G, Ram, PT, Nawrot, B & Sood, AK 2014, '2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity', Nature Communications, vol. 5, 3459. https://doi.org/10.1038/ncomms4459
Wu, Sherry Y. ; Yang, Xianbin ; Gharpure, Kshipra M. ; Hatakeyama, Hiroto ; Egli, Martin ; McGuire, Michael H. ; Nagaraja, Archana S. ; Miyake, Takahito M. ; Rupaimoole, Rajesha ; Pecot, Chad V. ; Taylor, Morgan ; Pradeep, Sunila ; Sierant, Malgorzata ; Rodriguez-Aguayo, Cristian ; Choi, Hyun J. ; Previs, Rebecca A. ; Armaiz-Pena, Guillermo N. ; Huang, Li ; Martinez, Carlos ; Hassell, Tom ; Ivan, Cristina ; Sehgal, Vasudha ; Singhania, Richa ; Han, Hee Dong ; Su, Chang ; Kim, Ji Hoon ; Dalton, Heather J. ; Kovvali, Chandra ; Keyomarsi, Khandan ; McMillan, Nigel A.J. ; Overwijk, Willem W. ; Liu, Jinsong ; Lee, Ju Seog ; Baggerly, Keith A. ; Lopez-Berestein, Gabriel ; Ram, Prahlad T. ; Nawrot, Barbara ; Sood, Anil K. / 2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. In: Nature Communications. 2014 ; Vol. 5.
@article{bb8c07e9907448888d1da7c6db733d6a,
title = "2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity",
abstract = "Improving small interfering RNA (siRNA) efficacy in target cell populations remains a challenge to its clinical implementation. Here, we report a chemical modification, consisting of phosphorodithioate (PS2) and 2′-O-Methyl (2′-OMe) MePS2 on one nucleotide that significantly enhances potency and resistance to degradation for various siRNAs. We find enhanced potency stems from an unforeseen increase in siRNA loading to the RNA-induced silencing complex, likely due to the unique interaction mediated by 2′-OMe and PS2. We demonstrate the therapeutic utility of MePS2 siRNAs in chemoresistant ovarian cancer mouse models via targeting GRAM domain containing 1B (GRAMD1B), a protein involved in chemoresistance. GRAMD1B silencing is achieved in tumours following MePS2-modified siRNA treatment, leading to a synergistic anti-tumour effect in combination with paclitaxel. Given the previously limited success in enhancing siRNA potency with chemically modified siRNAs, our findings represent an important advance in siRNA design with the potential for application in numerous cancer types.",
author = "Wu, {Sherry Y.} and Xianbin Yang and Gharpure, {Kshipra M.} and Hiroto Hatakeyama and Martin Egli and McGuire, {Michael H.} and Nagaraja, {Archana S.} and Miyake, {Takahito M.} and Rajesha Rupaimoole and Pecot, {Chad V.} and Morgan Taylor and Sunila Pradeep and Malgorzata Sierant and Cristian Rodriguez-Aguayo and Choi, {Hyun J.} and Previs, {Rebecca A.} and Armaiz-Pena, {Guillermo N.} and Li Huang and Carlos Martinez and Tom Hassell and Cristina Ivan and Vasudha Sehgal and Richa Singhania and Han, {Hee Dong} and Chang Su and Kim, {Ji Hoon} and Dalton, {Heather J.} and Chandra Kovvali and Khandan Keyomarsi and McMillan, {Nigel A.J.} and Overwijk, {Willem W.} and Jinsong Liu and Lee, {Ju Seog} and Baggerly, {Keith A.} and Gabriel Lopez-Berestein and Ram, {Prahlad T.} and Barbara Nawrot and Sood, {Anil K.}",
year = "2014",
month = "3",
day = "12",
doi = "10.1038/ncomms4459",
language = "English",
volume = "5",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - 2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity

AU - Wu, Sherry Y.

AU - Yang, Xianbin

AU - Gharpure, Kshipra M.

AU - Hatakeyama, Hiroto

AU - Egli, Martin

AU - McGuire, Michael H.

AU - Nagaraja, Archana S.

AU - Miyake, Takahito M.

AU - Rupaimoole, Rajesha

AU - Pecot, Chad V.

AU - Taylor, Morgan

AU - Pradeep, Sunila

AU - Sierant, Malgorzata

AU - Rodriguez-Aguayo, Cristian

AU - Choi, Hyun J.

AU - Previs, Rebecca A.

AU - Armaiz-Pena, Guillermo N.

AU - Huang, Li

AU - Martinez, Carlos

AU - Hassell, Tom

AU - Ivan, Cristina

AU - Sehgal, Vasudha

AU - Singhania, Richa

AU - Han, Hee Dong

AU - Su, Chang

AU - Kim, Ji Hoon

AU - Dalton, Heather J.

AU - Kovvali, Chandra

AU - Keyomarsi, Khandan

AU - McMillan, Nigel A.J.

AU - Overwijk, Willem W.

AU - Liu, Jinsong

AU - Lee, Ju Seog

AU - Baggerly, Keith A.

AU - Lopez-Berestein, Gabriel

AU - Ram, Prahlad T.

AU - Nawrot, Barbara

AU - Sood, Anil K.

PY - 2014/3/12

Y1 - 2014/3/12

N2 - Improving small interfering RNA (siRNA) efficacy in target cell populations remains a challenge to its clinical implementation. Here, we report a chemical modification, consisting of phosphorodithioate (PS2) and 2′-O-Methyl (2′-OMe) MePS2 on one nucleotide that significantly enhances potency and resistance to degradation for various siRNAs. We find enhanced potency stems from an unforeseen increase in siRNA loading to the RNA-induced silencing complex, likely due to the unique interaction mediated by 2′-OMe and PS2. We demonstrate the therapeutic utility of MePS2 siRNAs in chemoresistant ovarian cancer mouse models via targeting GRAM domain containing 1B (GRAMD1B), a protein involved in chemoresistance. GRAMD1B silencing is achieved in tumours following MePS2-modified siRNA treatment, leading to a synergistic anti-tumour effect in combination with paclitaxel. Given the previously limited success in enhancing siRNA potency with chemically modified siRNAs, our findings represent an important advance in siRNA design with the potential for application in numerous cancer types.

AB - Improving small interfering RNA (siRNA) efficacy in target cell populations remains a challenge to its clinical implementation. Here, we report a chemical modification, consisting of phosphorodithioate (PS2) and 2′-O-Methyl (2′-OMe) MePS2 on one nucleotide that significantly enhances potency and resistance to degradation for various siRNAs. We find enhanced potency stems from an unforeseen increase in siRNA loading to the RNA-induced silencing complex, likely due to the unique interaction mediated by 2′-OMe and PS2. We demonstrate the therapeutic utility of MePS2 siRNAs in chemoresistant ovarian cancer mouse models via targeting GRAM domain containing 1B (GRAMD1B), a protein involved in chemoresistance. GRAMD1B silencing is achieved in tumours following MePS2-modified siRNA treatment, leading to a synergistic anti-tumour effect in combination with paclitaxel. Given the previously limited success in enhancing siRNA potency with chemically modified siRNAs, our findings represent an important advance in siRNA design with the potential for application in numerous cancer types.

UR - http://www.scopus.com/inward/record.url?scp=84896259886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896259886&partnerID=8YFLogxK

U2 - 10.1038/ncomms4459

DO - 10.1038/ncomms4459

M3 - Article

VL - 5

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 3459

ER -